Ardelyx (ARDX) Reports Break-Even Earnings for Q4

分组1 - Ardelyx reported break-even quarterly earnings per share, matching the Zacks Consensus Estimate of $0.02, with a year-ago comparison of $0.02 per share [1] - The company achieved revenues of $125.22 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 6.51% and showing an increase from $116.13 million year-over-year [2] - Ardelyx shares have increased approximately 15.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] 分组2 - The earnings outlook for Ardelyx is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $111.28 million, and for the current fiscal year, it is $0.23 on revenues of $534.79 million [7] - The Medical - Drugs industry, to which Ardelyx belongs, is currently ranked in the bottom 47% of over 250 Zacks industries, indicating potential challenges for stock performance [8]